Challenges to leveraging real-world evidence for FDA approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The number of approved cancer therapies continues to rise, with 63 cancer drugs launched within the past five years.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ash Malik
Chief Strategy Officer, Life Sciences Division, Integra Connect
Table of Contents

YOU MAY BE INTERESTED IN

Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.
Ash Malik
Chief Strategy Officer, Life Sciences Division, Integra Connect

Login